Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159640891> ?p ?o ?g. }
- W3159640891 endingPage "1288" @default.
- W3159640891 startingPage "1267" @default.
- W3159640891 abstract "Although immune checkpoint inhibitors (ICIs) that target programmed cell death protein-1/programmed cell death ligand-1 axis have significantly shifted the treatment paradigm in advanced NSCLC, clinical benefits of these agents are limited in patients with EGFR-mutated NSCLC. Several predictive biomarkers (e.g., programmed cell death ligand-1 expression, tumor mutation burden), which have been validated in EGFR-wild type NSCLC, however, are not efficacious in EGFR-mutated tumors, suggesting the unique characteristics of tumor microenvironment of EGFR-mutated NSCLC. Here, we first summarized the clinical evidence on the efficacy of ICIs in patients with EGFR-mutated NSCLC. Then, the cancer immunogram features of EGFR-mutated NSCLC was depicted to visualize the state of cancer-immune system interactions, including tumor foreignness, tumor sensitivity to immune effectors, metabolism, general immune status, immune cell infiltration, cytokines, and soluble molecules. We further discussed the potential subpopulations with EGFR mutations that could benefit from ICI treatment. Lastly, we put forward future strategies to adequately maximize the efficacy of ICI treatment in patients with EGFR-mutated NSCLC in the upcoming era of combination immunotherapies." @default.
- W3159640891 created "2021-05-10" @default.
- W3159640891 creator A5006613618 @default.
- W3159640891 creator A5008421599 @default.
- W3159640891 creator A5016049048 @default.
- W3159640891 creator A5021941803 @default.
- W3159640891 creator A5023366097 @default.
- W3159640891 creator A5030449789 @default.
- W3159640891 creator A5055029433 @default.
- W3159640891 creator A5078919241 @default.
- W3159640891 creator A5080191032 @default.
- W3159640891 creator A5080382748 @default.
- W3159640891 date "2021-08-01" @default.
- W3159640891 modified "2023-10-15" @default.
- W3159640891 title "Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?" @default.
- W3159640891 cites W1480357432 @default.
- W3159640891 cites W1594203091 @default.
- W3159640891 cites W1658471897 @default.
- W3159640891 cites W1762620449 @default.
- W3159640891 cites W1889335134 @default.
- W3159640891 cites W1964081894 @default.
- W3159640891 cites W1967263367 @default.
- W3159640891 cites W1972825083 @default.
- W3159640891 cites W1975929837 @default.
- W3159640891 cites W1977819526 @default.
- W3159640891 cites W1978295910 @default.
- W3159640891 cites W1984557698 @default.
- W3159640891 cites W1986606168 @default.
- W3159640891 cites W1987431901 @default.
- W3159640891 cites W1988224733 @default.
- W3159640891 cites W2004150448 @default.
- W3159640891 cites W2007553857 @default.
- W3159640891 cites W2008075361 @default.
- W3159640891 cites W2008264147 @default.
- W3159640891 cites W2011458181 @default.
- W3159640891 cites W2022014232 @default.
- W3159640891 cites W2022633707 @default.
- W3159640891 cites W2025193872 @default.
- W3159640891 cites W2026909572 @default.
- W3159640891 cites W2040299716 @default.
- W3159640891 cites W2049491375 @default.
- W3159640891 cites W2049553585 @default.
- W3159640891 cites W2081801534 @default.
- W3159640891 cites W2088270805 @default.
- W3159640891 cites W2089187782 @default.
- W3159640891 cites W2096198395 @default.
- W3159640891 cites W2104065243 @default.
- W3159640891 cites W2104347254 @default.
- W3159640891 cites W2108933323 @default.
- W3159640891 cites W2114300975 @default.
- W3159640891 cites W2115786482 @default.
- W3159640891 cites W2117412547 @default.
- W3159640891 cites W2119490571 @default.
- W3159640891 cites W2123918574 @default.
- W3159640891 cites W2131233013 @default.
- W3159640891 cites W2131758778 @default.
- W3159640891 cites W2134122465 @default.
- W3159640891 cites W2136799969 @default.
- W3159640891 cites W2144174481 @default.
- W3159640891 cites W2145411470 @default.
- W3159640891 cites W2147592245 @default.
- W3159640891 cites W2152765064 @default.
- W3159640891 cites W2156353875 @default.
- W3159640891 cites W2160982674 @default.
- W3159640891 cites W2166084034 @default.
- W3159640891 cites W2170725294 @default.
- W3159640891 cites W2198093519 @default.
- W3159640891 cites W2221432805 @default.
- W3159640891 cites W2256341952 @default.
- W3159640891 cites W2288565689 @default.
- W3159640891 cites W2293064244 @default.
- W3159640891 cites W2293531514 @default.
- W3159640891 cites W2326735612 @default.
- W3159640891 cites W2346108121 @default.
- W3159640891 cites W2400514548 @default.
- W3159640891 cites W2444016033 @default.
- W3159640891 cites W2464190812 @default.
- W3159640891 cites W2464620827 @default.
- W3159640891 cites W2468576628 @default.
- W3159640891 cites W2494860457 @default.
- W3159640891 cites W2495882144 @default.
- W3159640891 cites W2516619560 @default.
- W3159640891 cites W2527905628 @default.
- W3159640891 cites W2538232731 @default.
- W3159640891 cites W2547310148 @default.
- W3159640891 cites W2560704457 @default.
- W3159640891 cites W2561459036 @default.
- W3159640891 cites W2563590437 @default.
- W3159640891 cites W2564483746 @default.
- W3159640891 cites W2565077351 @default.
- W3159640891 cites W2567564314 @default.
- W3159640891 cites W2589909473 @default.
- W3159640891 cites W2596766428 @default.
- W3159640891 cites W2601621622 @default.
- W3159640891 cites W2606022415 @default.
- W3159640891 cites W2606495925 @default.
- W3159640891 cites W2606966373 @default.
- W3159640891 cites W2613068810 @default.